Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of ...
Fintel reports that on September 8, 2025, Mizuho initiated coverage of KALA BIO (NasdaqCM:KALA) with a Outperform recommendation. Analyst Price Forecast Suggests 29.69% Upside As of September 3, 2025, ...
Small businesses in Latin America got another boost in lending support with the investment of $4 million in Kala, a Colombia-based company building fintech infrastructure for lending. The company, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback